Curcumin analogue, A13, exhibits anti-leukemia effect via inhibiting STAT3
Abnormal activation of signal transducer and activator of transcription 3 (STAT3) was reported in some leukemia, and inhibition of STAT3 can be the strategy for the leukemia treatment in clinic. In this study, we tested the anti-tumor effect of compound A13, a water-soluble analogue of curcumin, in vitro and in vivo. Herein, we show that A13 was able to reduce the viability of mastocytoma (P815 cells) and reticulum cell sarcoma (A20 cells) as measured by MTS assay. This effect was accompanied by a marked increase in the proportion of apoptotic cells as measured by flow cytometry. Furthermore, Western blot analysis suggested that the anti-leukemia effect of A13 was realized via STAT3 inhibition. In addition, systemic treatment with A13 in the A20-bearing mice for 60 days resulted in a significant improvement of survival rate and marked reduction of liver metastasis. In summary, our data show that the A13 treatment could effectively be applied to acute leukemia via inhibiting STAT3 signaling pathway.
KeywordsCurcumin analogue Water-soluble Anti-leukemia STAT3
The authors thank Professor Yong-Guang Yang from the Columbia Center for Translational Immunology, Columbia University Medical Center (New York, NY), for providing the A20 cell line, which was obtained from the American Type Culture Collection (ATCC).
This study was supported by the National Natural Science Funding of China (81102452 to Y.W.) and Natural Science Funding of Zhejiang (LQ16H160019 to Q.W.).
Compliance with ethical standards
Conflicts of interest
- 5.Adamaki M, Tsotra M, Vlahopoulos S, Zampogiannis A, Papavassiliou AG, Moschovi M. STAT transcript levels in childhood acute lymphoblastic leukemia: STAT1 and STAT3 transcript correlations. Leuk Res. 2015;S0145-2126(15):30379–9.Google Scholar
- 22.Kunnumakkara AB, Nair AS, Sung B, Pandey MK, Aggarwal BB. Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol Cancer Res. 2009;7:118–28.CrossRefPubMedPubMedCentralGoogle Scholar